Mechanism of Sanliangsan Lipid-Lowering in treating hyperlipidemia: insights from network pharmacology and molecular docking
Ze Yu, YaMin Hu, Wang Lv, Yaqi Wang, Yufei Yang
This study identifies active ingredients, key targets, and signaling pathways of Sanliangsan Lipid-Lowering for hyperlipidemia using network pharmacology and molecular docking, revealing a multi-component, multi-target, multi-pathway mechanism.
bioRxiv · Sep 25, 2025 · PreprintMolecular Biology